

The Pan-Inhibitor of Aurora Kinases Danusertib Induces Apoptosis and Autophagy and Suppresses Epithelial-to-Mesenchymal Transition in Human Breast Cancer Cells [Retraction]

Li JP, Yang YX, Liu QL, et al. *Drug Des Devel Ther.* 2015;9:1027–1062. <https://doi.org/10.2147/DDDT.S74412>

We, the Editors and Publisher of the journal, *Drug Design, Development and Therapy*, have retracted the published article.

After publication, concerns have been raised by a third party in 2025 about the integrity of the data in Figures 4 and 6 of the article.

Further investigation conducted by the Journal and Publisher confirmed the following:

- Unexpected similarities between the Western blots and the flow cytometry plots with the authors' other publication that are representative of different proteins and/or experimental conditions:
Li JP, Yang YX, Liu QL, et al. RETRACTED ARTICLE: The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. *Drug Des Devel Ther.* 2015;9:1627–1652. <https://doi.org/10.2147/DDDT.S75378>
- Unexpected similarities between the flow cytometry plots in Figure 9A, and in Figure 13A, that are representative of different samples and/or experimental conditions.
- Unexpected similarities between the Western blot data within the article that are representative of different proteins and/or experimental conditions.

When approached for an explanation, the authors checked their data and confirmed there are fundamental errors present. Therefore, they have agreed to the retraction of this article. The authors apologise for this oversight.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

Drug Design, Development and Therapy**Dovepress**

Taylor & Francis Group

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S633634>